Research
Independent biological evidence analysis. Every finding traceable to a specific database, query, and timestamp.
How to read these reports
Three terms appear throughout — define them once so flags are read as data, not accusation. Overstatement is a published claim that exceeds what the underlying source supports; most companies do this routinely. A Missing-data flag is a fact the deck implies but the agent cannot verify in any indexed primary source. PRR(proportional reporting ratio) is a pharmacovigilance metric — values above 2.0 with lower 95% CI > 1.0 are the WHO/UMC threshold for an adverse-event signal worth investigating.
Treat each flag as a data point. Investigate the ones that affect your decision.
- Immuneering Corporationdeep-cyclic MEK inhibitor (atebimetinib / IMM-1-104) · 1L metastatic pancreatic cancer
Atebimetinib + modified gem/nab-paclitaxel reported a 17.3-month median overall survival in first-line metastatic PDAC (N=55), against a MEK-in-PDAC record of two peer-reviewed failures. The full Phase 2a data present at ASCO abstract 4013 on June 1; it sets the MEK + chemotherapy control bar the RAS cluster is read against.
96 db - ASCO 2026 — RAS axis hub8 catalysts · 7 mechanistic branches · 35-paper bibliography
bigbio.ai reads each ASCO 2026 RAS-axis catalyst against the published mechanism record it inherits, names the questions the data will and will not answer, and updates as the Plenary lands. Five of eight catalysts sit on the KRAS axis; three are read as reference catalysts against the same audit gates.
359 db - Moderna, Inc.modRNA platform · seasonal respiratory + oncology
Four prophylactic mRNA approvals shipped. mRNA-1010 PDUFA August 5; INTerpath-001 melanoma readout next. The strain-B liability that felled Sanofi and Pfizer/BioNTech still applies.
1467 db - Corbus Pharmaceuticals Holdingsnectin-4 ADC · 2L head and neck + cervical cancer
CRB-701 ORR 47.6% in 2L head and neck. Zero peer-reviewed data. Pliant’s αvβ8 lead boxes out CRB-913.
226 db - Relay Therapeutics, Inc.FGFR2 + mutant-selective PI3Kα · solid tumors
Mechanism validated by prior art. The 490-patient ReFocus finished in September. The data still has not appeared.
364 db - Immunome, Inc.gamma-secretase inhibitor · desmoid tumor
Phase 3 hazard ratio 0.16. NDA filed April 29. ASCO oral on May 30 fills in subgroup detail.
9717 db - IDEAYA Biosciences, Inc.PKC inhibitor + c-MET · HLA*A2(-) metastatic uveal melanoma
OptimUM-02 hit. HR 0.42, mPFS 6.9 vs 3.1 mo. NDA H2 2026. ASCO LBA9503 fills in the rest June 1.
155 db - Wave Life SciencesGalNAc-conjugated AIMer · alpha-1 antitrypsin deficiency
GalNAc cleared 11 µM where one LNP didn’t. Beam’s LNP cleared it harder.
157 db - Compass TherapeuticsDLL4×VEGF-A bispecific · biliary tract cancer
Primary hit. Secondary hit. OS missed because 54% of placebo crossed over.
5214 db - Absci CorporationAI antibody design · oncology
The AI designs antibodies. The clinic opened eleven months ago.
10616 db - Abivax SASTAT3 inhibition · ulcerative colitis
Two Phase 3 induction wins. Nine billion dollars. One maintenance readout to go.
9318 db - Neurogene Inc.gene therapy · Rett syndrome
The high dose was fatal. The low dose has to beat a rival posting 100% response.
8922 db - Rezolute, Inc.anti-INSR mAb · congenital hyperinsulinism
Phase 3 missed both endpoints. The placebo arm responded at 40%.
8419 db